Effect of bisphosphonates on bone

  • Research type

    Research Study

  • Full title

    The effect of bisohosphonate administration on bone

  • IRAS ID

    239216

  • Contact name

    David Gibbs

  • Contact email

    d.gibbs@soton.ac.uk

  • Sponsor organisation

    University of Southampton

  • Clinicaltrials.gov Identifier

    32161, 32161

  • Duration of Study in the UK

    6 years, 0 months, 1 days

  • Research summary

    Bisphosphonates are medicines which are widely used in clinical practice, namely in treatment the of osteoporosis, Padgets disease of the bone, and to prevent the spread of cancer to the bone. Bisphosphonates are known to have an effect on osteoclasts, which are cells which break down bone. The effect of bishosphonate administration on other cells found in the bone, such as osteoblasts which make bone material, and osteocytes which co ordinate bone formation and bone breakdown is incompletely understood. Furthermore, the optimal duration of therapy with bisphosphonates is not known. We currently have ethical approval for the use of surplus tissue from patients undergoing surgery for hip fractures and arthritis at Southampton General Hospital (IRAS 234701). We would like to correlate the behaviour of the cells in the samples we currently receive from patients undergoing hip replacement surgery with additional patient information, namely if the patient is on bisphosphonates and other details routinely recorded in the patients notes and drug chart on admission to hospital relevant to osteoporosis.

  • REC name

    London - Stanmore Research Ethics Committee

  • REC reference

    18/LO/0902

  • Date of REC Opinion

    6 Jun 2018

  • REC opinion

    Further Information Favourable Opinion